3 days Ago
Myriad Genetics, Inc. ( NASDAQ: MYGN ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President of Investor Relations Paul Diaz - President and Chief Executive Officer Scott Leffler - Chief Financial Officer Sam Raha - Chief Operating Officer Mark Verratti - Chief Commercial Officer Conference Call Participants Douglas Schenkel - Wolfe Research Puneet Souda - Leerink Partners Prashant Kota - Goldman Sachs Subu Nambi - Guggenheim Partners Sung Ji Nam - Scotiabank Rachel Vatnsdal - JPMorgan Brandon Couillard - Wells Fargo Tycho Peterson - Jefferies Kyle Boucher - TD Cowen John Kim - Bank of America Operator Good afternoon, and welcome to the Myriad Genetics Third Quarter 2024 Financial Earnings. I am Franz, and I'll be the operator assisting you today.
All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session [ Operator Instructions]. Thank you.
And I would like to turn the call over to Matt Scalo. Please go ahead. Matt Scalo Thank you, Franz, and good afternoon, and welcome to the Myriad Genetics third quarter 2024 earnings call.
During the call, we will review financial results we released today. And afterwards, we will host a question-and-answer session. Our quarterly earnings release was issued this afternoon on Form 8-K and can be found on our website at investor.
myriad.com. I'm Matt Scalo, Senior Vice President of Investor Relations.
And on the call with me today are Paul Diaz, our President and Chief Executive Officer; Scott Leffler, our Chief Financial Officer; Sam Raha, our Chief Operating Officer; and Mark Verratti, our Chief Commercial Officer. This call can be heard live via webcast at investor.meriad.
com, and a recording will be archived in the Investors section of our website, along with the slide presentation..
